{"acquisitions":[],"changes":[],"country":"US","description":"R1 Therapeutics develops AP306, a first-in-class pan phosphate-transporter inhibitor that blocks GI phosphate absorption to treat hyperphosphatemia in chronic kidney disease. It targets CKD patients on dialysis or post-transplant. Active-transporter blockade replaces 9-15 binder pills a day, backed by a $77.5M Series A led by DaVita Venture Group.","domain":"r1therapeutics.com","employees":null,"founded":2022,"fundingTotalQuarantined":false,"githubOrg":null,"githubStars":null,"industry":"unknown","industrySources":[],"investors":[],"lat":42.358834,"lng":-71.05783,"location":"Boston","multiples":[],"name":"R1 Therapeutics","people":[],"revenues":[],"rounds":[{"amountQuarantined":false,"amountUsd":77500000,"connectionsAmong":[],"currency":"USD","date":"2026-03-17","investments":[],"investors":[],"leadInvestor":null,"leadInvestors":[],"people":[],"slug":"r1therapeutics-com-2026-03-17-series-a","source":{"fact":"round","publisher":"crunchbase","retrievedAt":"2026-06-14","status":"attributed","url":null},"status":"attributed","type":"series-a","url":null}],"slug":"r1therapeutics-com","sources":[{"fact":"round","publisher":"crunchbase","retrievedAt":"2026-06-14","status":"attributed","url":null},{"fact":"existence","publisher":"r1therapeutics.com","retrievedAt":"2026-06-14","status":"self-reported","url":"https://r1therapeutics.com"},{"fact":"description","publisher":"r1therapeutics.com","retrievedAt":"2026-06-14","status":"self-reported","url":"https://r1therapeutics.com"}],"stage":"series-a","stockCard":{"asOf":"2026-11-09","facts":[],"generatedAt":"2026-11-09","state":"insufficient-evidence","tldr":[]},"techStack":["cloudflare","cloudflare bot management","hsts","react","remix","styled-components","web-vitals"],"totalRaisedUsd":77500000,"traction":[],"updatedAt":"2026-06-14","valuations":[]}